Published in Ann Intern Med on January 16, 2001
Natural History of Post-transfusion Non-A, Non-B Hepatitis | NCT00005306
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology (2010) 2.64
The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63
Alcohol use and hepatitis C. Hepatology (2002) 1.55
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res (2006) 1.09
Management of chronic hepatitis C. Postgrad Med J (2005) 1.03
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases. World J Gastroenterol (2014) 0.96
KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol (2013) 0.87
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87
Natural history of hepatitis C infection: a concise review. Yale J Biol Med (2001) 0.87
Alcohol reversibly disrupts TNF-alpha/TACE interactions in the cell membrane. Respir Res (2005) 0.86
Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 0.84
Alcohol has no effect on hepatitis C virus replication: a meta-analysis. Gut (2005) 0.84
Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One (2013) 0.83
A Mechanistic Review of Mitophagy and Its Role in Protection against Alcoholic Liver Disease. Biomolecules (2015) 0.83
Enhanced chronic hepatitis C surveillance in New York City, April 2009-January 2011. Public Health Rep (2013) 0.82
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
Long-term effects of antiviral therapy in patients with chronic hepatitis C. Hepat Res Treat (2010) 0.81
Chronic alcohol-induced liver disease inhibits dendritic cell function. Liver Int (2011) 0.80
SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80
Clinical course of infection with hepatitis C. BMJ (2006) 0.79
Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Addict Behav (2009) 0.79
Increase in alcohol related deaths: is hepatitis C a factor? J Clin Pathol (2002) 0.78
Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study. World J Gastroenterol (2014) 0.78
Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. Addict Sci Clin Pract (2015) 0.75
Transcriptome Profiling Reveals Disruption of Innate Immunity in Chronic Heavy Ethanol Consuming Female Rhesus Macaques. PLoS One (2016) 0.75
Positive CAGE screen correlates with cirrhosis in veterans with chronic hepatitis C. Dig Dis Sci (2007) 0.75
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis (2000) 6.05
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 5.51
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med (2000) 5.27
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med (1991) 4.79
Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med (1991) 4.24
Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis (1981) 4.15
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology (1994) 4.01
Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol (1996) 3.59
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med (1997) 3.48
Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med (1975) 3.31
Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med (1993) 3.25
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol (1994) 3.06
Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis (1986) 3.03
Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med (1991) 3.02
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med (1992) 3.01
Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature (1982) 3.01
Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med (1990) 2.99
Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique. J Immunol (1971) 2.98
Microtiter solid-phase radioimmunoassay for hepatitis B antigen. Appl Microbiol (1973) 2.96
Transmissible agent in non-A, non-B hepatitis. Lancet (1978) 2.78
Non-A, non-B hepatitis: ultrastructural evidence for two agents in experimentally infected chimpanzees. Science (1979) 2.78
Airways obstruction and the risk for lung cancer. Ann Intern Med (1987) 2.77
Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood (1997) 2.74
Measurement of anticonvulsant adherence behaviour in the community using a Medication Events Monitoring System (MEMS) Health Care Anal (1998) 2.70
Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis (1987) 2.68
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med (1976) 2.67
What do western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors? Lancet (1989) 2.63
Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med (1995) 2.61
Dilution assay statistics. J Clin Microbiol (1994) 2.61
Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clin Pharmacol Ther (2009) 2.60
Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem (2000) 2.47
Clinical and serological analysis of transfusion-associated hepatitis. Lancet (1975) 2.41
Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology (2001) 2.38
Assay of Australia antigen and antibody employing double-antibody and solid-phase radioimmunoassay techniques and comparison with the passive hemagglutination methods. J Immunol (1971) 2.35
Detection of hepatitis A viral antigen by radioimmunoassay. J Immunol (1975) 2.33
Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem (2000) 2.30
Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med (1978) 2.30
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med (1981) 2.29
Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med (1986) 2.27
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25
Mouse allergen. II. The relationship of mouse allergen exposure to mouse sensitization and asthma morbidity in inner-city children with asthma. J Allergy Clin Immunol (2000) 2.20
Further studies on a "new" human isoprecipitin system (Australia antigen). Blood (1966) 2.16
Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis (1994) 2.15
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease. Arch Intern Med (1984) 2.07
High frequency of antibodies to Mycoplasma penetrans in HIV-infected patients. Lancet (1992) 2.06
Mouse allergen. I. The prevalence of mouse allergen in inner-city homes. The National Cooperative Inner-City Asthma Study. J Allergy Clin Immunol (2000) 2.05
A comparison of the frequency of hepatitis-B antigen and antibody in hospital and nonhospital personnel. N Engl J Med (1973) 2.05
Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci U S A (1990) 2.04
Infectious liver diseases in three groups of Copenhagen workers: correlation of hepatitis A infection to sewage exposure. Arch Environ Health (1981) 2.03
Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis (1989) 2.03
Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med (1984) 2.01
A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med (1994) 1.99
Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med (1981) 1.96
G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion (1997) 1.96
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med (1984) 1.93
Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med (1991) 1.91
Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology (2000) 1.87
Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis (1986) 1.87
Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis (2000) 1.87
Late relapse of testicular cancer. J Clin Oncol (1995) 1.87
Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group. ACTG PCR Working Group, and the ACTG PCR Virology Laboratories. J Clin Microbiol (1993) 1.85
Nonparenteral transmission of viral hepatitis type B (Australia antigen-associated serum hepatitis). N Engl J Med (1971) 1.84
Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet (1978) 1.82
Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol (1997) 1.81
Effect of hepatitis G virus infection on chronic hepatitis C. Ann Intern Med (1996) 1.81
SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology (2001) 1.80
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology (1997) 1.77
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol (1998) 1.72
Management of the asymptomatic carrier of the hepatitis-associated (Australia antigen. Tentative considerations of the clinical and public-health aspects. N Engl J Med (1971) 1.71
Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops. Am J Epidemiol (2001) 1.71
Importance of western blot analysis in predicting infectivity of anti-HTLV-III/LAV positive blood. Lancet (1985) 1.70
Biophysical and biochemical heterogeneity of purified hepatitis B antigen. J Virol (1972) 1.70
Identification of Mycoplasma incognitus infection in patients with AIDS: an immunohistochemical, in situ hybridization and ultrastructural study. Am J Trop Med Hyg (1989) 1.70
Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res Hum Retroviruses (1999) 1.66
Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg (1994) 1.65
Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med (1997) 1.65
Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A (1989) 1.64
Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood (1990) 1.64
Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med (1972) 1.64
A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med (1987) 1.61